These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 440651)

  • 21. CA-125 monitoring in the management of ovarian cancer.
    Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
    Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
    Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
    Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cellular immune function of patients with ovarian cancer before and after cancer therapy].
    Hamai J
    Nihon Gan Chiryo Gakkai Shi; 1985 Jul; 20(6):1146-62. PubMed ID: 3840828
    [No Abstract]   [Full Text] [Related]  

  • 25. Radical operation for recurring gastric carcinoma.
    Yamada H; Morita T; Fujita M; Miyasaka Y; Senmaru N; Oshikiri T
    Hepatogastroenterology; 2006; 53(68):309-12. PubMed ID: 16608046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA index by flow cytometric analysis: an additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation.
    Zanetta G; Keeney GL; Cha SS; Wieand HS; Katzmann JA; Podratz KC
    Gynecol Oncol; 1996 Aug; 62(2):208-12. PubMed ID: 8751551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of lymphocyte responses to phytohemagglutinin in melanoma patients. (lack o prognostic value of correlation with minimal tumor burden).
    Kovarík J; Ninger E; Zemanová D; Lauerová L
    Neoplasma; 1980; 27(5):575-82. PubMed ID: 7231613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
    Yang XJ; Li Y; al-shammaa Hassan AH; Yang GL; Liu SY; Lu YL; Zhang JW; Yonemura Y
    Ann Surg Oncol; 2009 Feb; 16(2):345-51. PubMed ID: 19018599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preactivated T cells in cancer patients with poor prognosis.
    Fuchs DN; Fuith LC; Hausen A; Hetzel H; Reibnegger GJ; Werner ER; Wachter H
    Cancer Detect Prev; 1988; 12(1-6):97-103. PubMed ID: 3141055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer.
    Reibnegger G; Hetzel H; Fuchs D; Fuith LC; Hausen A; Werner ER; Wachter H
    Cancer Res; 1987 Sep; 47(18):4977-81. PubMed ID: 3621185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 31 patients and prognostic factors.
    To EW; Lai EC; Cheng JH; Pang PC; Williams MD; Teo PM
    Laryngoscope; 2002 Oct; 112(10):1877-82. PubMed ID: 12368634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on nonspecific cellular immune response in patients with urinary bladder carcinoma.
    Nishio S; Morikawa Y; Horii A; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
    Osaka City Med J; 1978; 24(1):51-71. PubMed ID: 752146
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.